1. COVID-19: A Catalyst for Change for UK Clinical Oncology
- Author
-
Tom Roques, Peter Hoskin, Christopher M. Jones, Ananya Choudhury, Ben O'Leary, Hannah Tharmalingam, Frances A.P. Yuille, Charlotte E. Coles, Coles, Charlotte [0000-0003-4473-8552], and Apollo - University of Cambridge Repository
- Subjects
Clinical Oncology ,2019-20 coronavirus outbreak ,Cancer Research ,Radiation ,Coronavirus disease 2019 (COVID-19) ,34 Chemical Sciences ,business.industry ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,MEDLINE ,32 Biomedical and Clinical Sciences ,National health service ,3211 Oncology and Carcinogenesis ,5105 Medical and Biological Physics ,3407 Theoretical and Computational Chemistry ,Nursing ,Oncology ,Radiology Nuclear Medicine and imaging ,Pandemic ,Medicine ,Education and Training ,Radiology, Nuclear Medicine and imaging ,business ,51 Physical Sciences - Abstract
The United Kingdom has been severely affected by the coronavirus disease 2019 (COVID-19) pandemic. As the National Health Service (NHS) has urgently prioritized management of this outbreak, the UK clinical oncology community has had to adapt rapidly to maintain cancer services and training. These unprecedented times have altered countless aspects of cancer care, education, and research, providing a legacy that will extend well beyond the pandemic that catalyzed them. This editorial focuses on 3 key themes that distinguish the United Kingdom from many other countries.
- Published
- 2020